(2R,3R)-1-azido-3-phenylpropane-2,3-diol | 1190855-49-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (2R,3R)-1-azido-3-phenylpropane-2,3-diol
• 英文别名: (1R,2R)-3-azido-1-phenylpropane-1,2-diol
• CAS: 1190855-49-2
• 化学式: C₉H₁₁N₃O₂
• 分子量: 193.205
• InChiKey: LIVAZQCOAVMLPE-RKDXNWHRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  54.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (2R,3R)-1-azido-3-phenylpropane-2,3-diol 在 10% palladium on activated carbon 、 氢气 作用下， 以 乙酸乙酯 为溶剂， 反应 24.0h， 以90%的产率得到(2R,3R)-1-amino-3-phenylpropane-2,3-diol
  参考文献：
  名称：

  Design and synthesis of (2R,3S)-iodoreboxetine analogues for SPECT imaging of the noradrenaline transporter

  摘要：

  A stereoselective 10-step synthesis of iodophenoxy analogues of (2R,3S)-reboxetine has been developed with the aim of generating a new SPECT imaging agent for the noradrenaline transporter (NAT). In vitro testing of these compounds against various mono-amine transporters showed an ortho-iodophenoxy analogue to have excellent affinity (K-i 8.4 nM) and good selectivity for NAT. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.07.064
• 作为产物：
  描述：

  (2S,3R)-1-chloro-3-phenylpropane-2,3-diol 在 sodium azide 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 44.0h， 以85%的产率得到(2R,3R)-1-azido-3-phenylpropane-2,3-diol
  参考文献：
  名称：

  Design and synthesis of (2R,3S)-iodoreboxetine analogues for SPECT imaging of the noradrenaline transporter

  摘要：

  A stereoselective 10-step synthesis of iodophenoxy analogues of (2R,3S)-reboxetine has been developed with the aim of generating a new SPECT imaging agent for the noradrenaline transporter (NAT). In vitro testing of these compounds against various mono-amine transporters showed an ortho-iodophenoxy analogue to have excellent affinity (K-i 8.4 nM) and good selectivity for NAT. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.07.064

文献信息

• [EN] NICOTINAMIDE RIPK1 INHIBITORS<br/>[FR] INHIBITEURS DE NICOTINAMIDE RIPK1
  申请人：[en]ABBVIE INC.

  公开号：WO2023018643A1

  公开（公告）日：2023-02-16

  Provided herein are compounds of Formula (I) and pharmaceutically acceptable salts thereof, useful as RIPK1 inhibitors, and pharmaceutical compositions comprising same. Further provided are methods of use and preparation. (I)